Frazier Life Sciences Management L.P. established a new position in Kailera Therapeutics, Inc. by acquiring 1,100,000 shares. The stake is valued at approximately $24.23 million. This acquisition gives the venture firm a 0.85% ownership interest in the company.
The investment follows a $113.9 million position taken by Atlas Venture Life Science Advisors LLC during the same quarter. Kailera Therapeutics focuses on the development of GLP-1-based obesity treatments. These substantial institutional investments signal strong market confidence in the company’s clinical pipeline.